Shire’s Vpriv wins Lysosomal Disease Network award

Shire has announced that Vpriv, its innovative enzyme replacement therapy for type 1 Gaucher disease, has received an award from the Lysosomal Disease Network.

The international research network has presented its inaugural novel treatment award to Shire's drug in recognition of the considerable contribution it has made in addressing the need of lysosomal disease sufferers.

Having proven the safety and efficacy of Vpriv in clinical trials involving more than 100 patients, Shire has made the drug available in 40 countries to date, including the US, the member states of the EU and Israel.

It is manufactured using a human cell line with Shire's proprietary gene activation technology and contains the exact human amino acid sequence found in the naturally occurring human enzyme.

Dr Philip Vickers, global head of research and development at Shire HGT, said: "Every employee at Shire is dedicated to developing and bringing forward new products, services and support offerings which can make a positive impact on patients' lives."

This comes in the same month the company made its new attention deficit hyperactivity disorder treatment Elvanse available to UK patients for the first time.